PTPRC and neoplasm: Most interestingly, the percentages of CD45+CD8+ cells (Fig. 3c) and effector CD8+IFN-γ+ T cells (Fig. 3d) in the tumors treated by E7 + RT was about 4-fold higher than in the tumor treated by RT + E7 or by RT alone.